

Sanity Group Becomes Part of Canadian Cannabis Market Leader Organigram Global to Drive International Growth

- **Germany's leading medical cannabis company, Sanity Group has entered strategic agreement with longtime investor and partner, Organigram Global Inc.**
- **Transaction valuation: Sanity Group has been valued at a total of up to EUR 250 million, consisting of an upfront EUR 130 million and up to EUR 120 million linked to defined performance metrics for twelve months ending March 31, 2027**
- **This catalyzes Sanity Group's long term international growth and international expansion across the European cannabis market**

Berlin, February 18, 2026 – As one of Germany's leading companies in the medical cannabis sector, Sanity Group has entered into an agreement on a strategic transaction with its long-standing investor and production partner, Organigram Global Inc. ("Organigram"). Based on two highly complementary business models, the two companies are pursuing an integrated approach that prioritizes global growth, diversification of the product portfolio, and, in turn, a sustainable improvement in the supply of cannabis patients. The publicly listed¹ Toronto-headquartered company Organigram contributes extensive expertise in quality-assured cultivation, processing and innovative cannabis product development to the partnership—complementing Sanity Group's capabilities and experience to create a strong foundation for long-term growth and international expansion across the European cannabis market. Sanity Group will continue to focus on the pharmaceutical segment, confirms founder and CEO Finn Hänsel: "Building on our complementary strengths and synergies, we and Organigram plan not only to sustainably secure the supply of cannabis for patients in Europe, but to strengthen it over the long term. Our focus on distributing medical cannabis to pharmacies, as well as on scientific research and innovation, therefore remains unchanged."

The strategic partnership strengthens the companies' joint position as emerging players in the global cannabis market, starting from two of the world's largest medical cannabis markets—Germany and Canada. With its established network of strong partners across the entire value chain, as well as comprehensive regulatory, pharmaceutical and operational expertise, Sanity Group will complement Organigram Global going forward as its European platform with local management in place. No changes to day-to-day operations or the corporate structure are planned at this time. "Based on our partnership to date, I have great confidence in both companies' vision to scale internationally," said Finn Hänsel. "Together we will unlock multifaceted growth opportunities, particularly through entry into new European markets. Organigram has already proven to be an exceptional partner, with deep expertise in cultivation, manufacturing, patient-focused research and innovation. These strengths will be critical in actively shaping the global cannabis market. Our strategic objective is to build a global market leader over the coming years."

Patient Care, Research and Development as Key Pillars

As part of the proposed transaction, Sanity Group has been valued at a total of up to EUR 250 million, comprising an upfront EUR 130 million and up to EUR 120 million linked to defined performance metrics for twelve months ending March 31, 2027. Decisions regarding a future governance structure have deliberately not yet been made. "At present, our primary focus is on thoughtful integration and the creation of long-term value, rather than on rapid structural changes," explained Seyit Kaya, CFO of Sanity Group.

¹ Organigram Global Inc. is listed on both the Nasdaq and the Toronto Stock Exchange under the ticker symbol "OGI"

In addition to the continued sourcing of high-quality medical cannabis products, Sanity Group sees significant added value in the merger with Organigram particularly in the areas of research and development for patient care. Through clinical trials of cannabinoid-based medicines and the development of innovative dosage forms, collaboration between the two teams is expected to generate scientifically grounded product innovations for the European medical cannabis market. The Sanity Group shareholders nominated Max Narr, Sanity Group's former managing director and Chief Strategy & Investment Officer, to represent Sanity Group within the Organigram Global board. Max Narr has also been deeply engaged in this transaction as an advisor to the Sanity Group.

From Berlin Startup to European Pioneer

Founded in 2018, Berlin-based Sanity Group is among the best-known and most successful cannabis companies in Europe. Strong revenue growth—from EUR 9 million in 2023 to EUR 60 million in 2025—has secured the company the second-largest market share in Germany. In addition to a diversified brand and product portfolio, deep regulatory expertise and a strong partner network, the company also brings substantial experience in adult-use cannabis research. As the only German company participating in a scientific pilot project exploring the legal distribution of adult-use cannabis in Switzerland, Sanity Group operates Europe's first two legal cannabis specialty stores as part of that initiative.

Canadian Market Leader Pursues International Expansion

Organigram, a publicly traded cannabis producer with cultivation, processing and logistics facilities across several Canadian provinces, ranks among the world's leading specialized cannabis companies. In cooperation with Sanity Group, it is now expanding its international footprint to assume a leading role in Europe. The partners aim to establish patient-centric brands, new product innovations and proven business models across European medical markets, including Germany, Poland, the United Kingdom and Switzerland. Over the longer term, newly emerging legal adult-use markets are also expected to become relevant.

"The future collaboration represents a pivotal step on Organigram's journey to realize our ambition of becoming a global market leader in the rapidly growing cannabis industry. This transformative transaction brings together two market leaders, immediately expands our commercial presence in Europe and strengthens our competitive position in the world's largest legal cannabis markets," said James Yamanaka, CEO of Organigram.

+++

Members of the media may obtain further detailed information regarding the transaction from Organigram's public communications.

About Sanity Group

Sanity Group aims to improve people's quality of life through the use of cannabinoids and the utilization of the endocannabinoid system. The focus is on cannabinoid-based pharmaceuticals and consumer goods. To harness the full potential of cannabis, Sanity Group invests in research of the cannabis plant and its active ingredients as well as in specific areas of application. Sanity Group, founded in Berlin in 2018 by Finn Age Hänsel, includes Vayamed, avaay Medical and ZOIKS (medical cannabis), Endosane Pharmaceuticals (finished pharmaceuticals), vaay (lifestyle) and Grashaus Projects (scientific pilot project on recreational cannabis in Switzerland). Near Frankfurt am Main, Sanity Group also operates a logistics and production facility for cannabis pharmaceuticals. More information at sanitygroup.com/press.

About Organigram Global Inc.

Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project Limited, Organigram Global participates in the U.S. and Canadian cannabinoid beverage markets. Organigram is focused on producing

high-quality cannabis for adult consumers, as well as developing international business partnerships to extend the Company's global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Collective Project, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).